Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2020

Primary Completion Date

January 1, 2022

Study Completion Date

June 1, 2022

Conditions
SARS-CoV-2 PneumoniaCOVID-19
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.

Trial Locations (1)

83814

Kootenai Health, Coeur d'Alene

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Washington State University

OTHER

lead

Kootenai Health

OTHER